Get intelligentvalue.com

Own it today or select a payment plan

Buy Now$3,879Payment Plan$325/mo

Secured by Stripe

Premium Domain Name

intelligentvalue.com

is available for purchase

51 views

Visitors from

US 54%·

AU 32%·

IN 7%·

GB 2%·

FR 2%

Perfect for

Financial Consulting Technology Startups Educational Services Economic Forecasting E-commerce Solutions Business Analytics Artificial Intelligence Solutions Investment Advisory Strategic Planning Market Research

Unlock the potential of 'intelligentvalue.com', a premium domain that embodies sophistication and expertise in investment advisory and financial consulting. Perfect for businesses in artificial intelligence solutions, market research, and strategic planning, this memorable domain conveys a strong branding message that resonates with clients seeking innovative and data-driven insights. Elevate your presence in the competitive landscape with a digital identity that signifies intelligence, value, and forward-thinking solutions.

Safe & Secure

Protected transactions with Stripe

Fast Transfer

Domain transferred within 24 hours

Flexible Payments

Interest-free payment plans available

Tevogen to Share Direct Registration System (DRS) Process Details Following Increased Shareholder Interest

May 02, 2025 at 15:45 PM EDT

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

WARREN, N.J., May 02, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced that, following the Company’s recent press release highlighting the Direct Registration System (DRS) as a secure method of share ownership, it has received a number of inquiries from shareholders seeking additional information on how to transfer their shares to a DRS account.

In response, Tevogen will provide step-by-step guidance early next week to help interested shareholders register their shares directly with the Company’s transfer agent, Continental Stock Transfer & Trust.

The Company also notes that several of its largest shareholders, both internal and external, have elected to hold their shares via DRS, underscoring their confidence in this method of direct ownership.

Contacts

Tevogen Bio Communications

T: 1 877 TEVOGEN, Ext 701

Communications@Tevogen.com